|
Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN) Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN) conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN) Clinical research trials and Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN) healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN). Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN) Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN) clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN) condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "F" Clinical Trials Conditions > Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN)  Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN)
Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN)
For Condition: Coronary Arteriosclerosis,Heart Diseases,Atherosclerosis,Cardiovascular Diseases
Status: No longer recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To determine familial and non-familial causes for susceptibility to atherosclerosis and the inflammatory response.
Details: BACKGROUND: Atherosclerotic cardiovascular disease, along with its related health expenditures, mortality, and morbidity, remains among the most significant health-related conditions in the United States and other developed countries. The substantial resources that have been expended to investigate this problem have led to significant scientific advances in the basic biology, clinical management, epidemiology, and public health intervention approaches. Despite these real advances, there remains much more to be done in terms of understanding the basic biological and social processes, treatment, and public health programs. Just as earlier research was effective in identifying a variety of epidemiologic risk factors for cardiovascular disease, recent advances make it possible to bring to bear a variety of new and powerful tools to detailed study of the basic processes involved in atherogenesis. Application of these tools, in combination with synthesis of prior basic and epidemiologic results, provides a powerful approach that is more model-driven than many previous studies. DESIGN NARRATIVE: GENCAC is a multicenter study of the genetic epidemiology of coronary and aortic calcification and of inflammatory markers. It examines two areas of great interest in contemporary vascular medicine, namely vascular calcification and inflammation in approximately 3000 persons who have been recruited to the Family Heart Study, with additional persons of African American descent contributed by the HyperGEN Study. Considerable data, including a large number of genotypes, have been collected in the Family Heart Study. The subjects will be brought back for additional data collection, including the measurement of inflammatory markers and coronary and aortic calcification by computed tomography (CT). GENCAC will quantify coronary and aortic artery calcium volume in 441 selected, informative pedigrees ( approximately 3,000 individuals) previously examined and extensively genotyped ( approximately 400 markers spanning the genome) by the NHLBI Family Heart Study, in order to identify genes associated with human atherosclerosis. An additional 275 African American sibships (approximately 600 individuals, also examined and comparably genotyped) will be included to address these study questions in this high-risk population. Assessment of the inter-individual variability in the inflammatory burden and the host response, and the extensive metabolic, behavioral, and environmental data already collected on these pedigrees will provide enhanced phenotypic homogeneity and increased analytic power in assessing the genetic basis of atherosclerosis. State of the art laboratory and statistical methods will be used to find, localize and characterize the influence of predisposing genes to atherosclerosis and the inflammatory response. Novel genetic analysis methods will be used to address the issues of phenotypic, genetic and population heterogeneity, epistasis, complex interactions among the genetic and environmental risk factors, and to optimize the detection of genomic regions affecting phenotypic susceptibility.
Eligibility:
Study Type: Observational, Natural History, Defined Population
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JohnCarr, , Wake Forest University
Additional Information:
Study ID Numbers: 985;
Study Start Date: September 2001
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00024596
Other Atherosclerosis Studies:
1. Apolipoprotein Polymorphisms and Risk of Coronary Heart Disease
2. Pediatric Cardiomyopathy Registry
3. Women's Health Initiative (WHI)
4. Homocyst(e)ine, Vitamin Status, and CVD Risk
5. The safety and efficacy of adjunct carvedilol in children with moderate heart failure
Related Studies:
Other Atherosclerosis Clinical Trials
Other Clinical Trials
Other Clinical Trials
Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN)
|
|
|
|
|
|
|
|
